Three Vascepa trial protocols currently recruiting per clinicaltrials.gov | AMRN Message Board Posts

Amarin Corporation plc

  AMRN website

AMRN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  7336 of 7359  at  6/30/2020 10:09:17 AM  by

JBWIN


Three Vascepa trial protocols currently recruiting per clinicaltrials.gov

 1.  

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S.
Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04412018
Recruitment Status : Recruiting
First Posted : June 2, 2020
Last Update Posted : June 5, 2020
Sponsor:
Collaborators:
Amarin Corporation
HLS Therapeutics, Inc
Information provided by (Responsible Party):
Canadian Medical and Surgical Knowledge Translation Research Group

Study Description
Go to
Brief Summary:
This is a 14-day long prospective, multi-site, two-armed, randomized, open-label study that will enroll approximately 100 adult outpatients in Canada who have received a positive SARS-CoV-2 test result within the preceding 72 hours. Participants will be randomized (1:1) to receive either icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days) or usual care. Blood samples will be collected to determine if icosapent ethyl use lowers circulating pro-inflammatory biomarkers.

Condition or disease Intervention/treatment Phase
COVID-19Inflammatory ResponseDrug: Icosapent ethylPhase 2
Study Design
Go to
Study Type :Interventional (Clinical Trial)
Estimated Enrollment :100 participants
Allocation:Randomized
Intervention Model:Parallel Assignment
Masking:None (Open Label)
Primary Purpose:Treatment
Official Title:An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)
Estimated Study Start Date :June 2020
Estimated Primary Completion Date :December 2020
Estimated Study Completion Date :December 2020
Resource links provided by the National Library of MedicineDrug Information available for: Icosapent Ethyl icosapentate Icosapent ethyl
Arms and Interventions
Go to
Arm Intervention/treatment
No Intervention: Usual Care
Participants in this arm will continue with usual care
Experimental: Icosapent Ethyl
Participants in this arm will take icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
Drug: Icosapent ethyl
Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
Other Name: Vascepa



Outcome Measures
Go to

Primary Outcome Measures :
  1. Change in hs-CRP levels from the randomization visit (Day 1) to the Day 14 visit [ Time Frame: 14 days ]

Secondary Outcome Measures :
  1. Change in D-dimer levels from the randomization visit (Day 1) to the Day 14 visit [ Time Frame: 14 days ]
  2. Change in erythrocyte sedimentation rate from the randomization visit (Day 1) to the Day 14 visit [ Time Frame: 14 days ]
  3. Change in complete blood count from the randomization visit (Day 1) to the Day 14 visit [ Time Frame: 14 days ]
  4. Change in differential count from the randomization visit (Day 1) to the Day 14 visit [ Time Frame: 14 days ]
  5. Change in serum albumin levels from the randomization visit (Day 1) to the Day 14 visit [ Time Frame: 14 days ]
  6. Change in neutrophil-to-lymphocyte ratio (NLR) from the randomization visit (Day 1) to the Day 14 visit [ Time Frame: 14 days ]
  7. Change in systemic immune-inflammation index from the randomization visit (Day 1) to the Day 14 visit [ Time Frame: 14 days ]

Other Outcome Measures:
  1. Change in FLU-PRO scores from the screening visit to the Day 14 visit [ Time Frame: 14 days ]

    Response options will be along one of the following formats:

    (i) 5-point Likert scale with answers ranging from (a) "Not at all" to "Very much" and (b) "Never" to "Always" (ii) Quantitative with answers ranging from "0 times" or "4 or more times" (iii) Binary response format (Yes or No)


  2. World Health Organization Symptom Severity Scale [ Time Frame: 14 days ]
    Response options will range from 0 to 6 with a higher value indicating a worse outcome

Eligibility Criteria
Go to

Information from the National Library of MedicineChoosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

  1. Positive local SARS-CoV-2 test result within the preceding 72 hours
  2. At least one of the following symptoms

    1. Fever
    2. Cough
    3. Sore throat
    4. Shortness of breath
    5. Myalgia

Exclusion Criteria:

  1. Individuals currently participating in another interventional trial that will or may interfere with the primary outcome
  2. Hospitalized individuals
  3. Individuals who have a current medical condition for which life expectancy is less than 3 months
  4. Individuals with a history of acute end-organ injury (e.g. myocardial infarction, stroke, hospitalization for acute lung, liver or kidney disease) within the last month
  5. Individuals with active severe liver disease
  6. Individuals with a history of acute or chronic pancreatitis
  7. Women who are pregnant, may be pregnant, are planning on becoming pregnant, or are lactating
  8. Women of child-bearing potential who are not using at least one form of highly effective (hormonal contraceptives [e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants]; intrauterine device or intrauterine system; tubal ligation or whose partner has had a vasectomy) and one effective (barrier methods such male condom, female condom, cervical cap, diaphragm, or contraceptive sponge) method of contraception
  9. Individuals with a history of hemodynamic instability within past 72 hours including a systolic blood pressure of <95 mmHg and/or a diastolic blood pressure of <50 mmHg
  10. Individuals with known hypersensitivity to fish and/or shellfish, or ingredients of IPE
  11. Individuals with any other condition which, in the opinion of the Investigator, would place the participant at increased risk, preclude obtaining voluntary consent or confound the objectives of study
  12. Individuals who are unable to swallow IPE capsules whole
Contacts and Locations
Go to

Information from the National Library of MedicineTo learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04412018


Contacts
Contact: Subodh Verma, MD, PhD1-416-864-5997subodh.verma@unityhealth.to
Contact: Hwee Teoh, PhDpostscripts@rogers.com

Locations
Canada, Ontario
North York Diagnostic and Cardiology ClinicRecruiting
Toronto, Ontario, Canada, M6B 3H7
Contact: Subodh Verma, MD, PhD
Sponsors and Collaborators
Canadian Medical and Surgical Knowledge Translation Research Group
Amarin Corporation
HLS Therapeutics, Inc
Investigators
Principal Investigator:Subodh Verma, MD, PhDCanadian Medical and Surgical Knowledge Translation Research Group
More Information
Go to
Responsible Party:Canadian Medical and Surgical Knowledge Translation Research Group
ClinicalTrials.gov Identifier:NCT04412018 History of Changes
Other Study ID Numbers:Pro00043601
First Posted:June 2, 2020 Key Record Dates
Last Update Posted:June 5, 2020
Last Verified:June 2020
 
2. 

EPA for Metastasis Trial 2 (EMT2)


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03428477
Recruitment Status : Recruiting
First Posted : February 9, 2018
Last Update Posted : November 1, 2019
Sponsor:
Collaborators:
Yorkshire Cancer Research
Amarin Pharma Inc.
Information provided by (Responsible Party):
Mark A Hull, PhD FRCP, University of Leeds

Study Description
Go to
Brief Summary:
A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop disease recurrence and die from the disease. A previous small study (the EMT study) suggested a possible survival benefit in patients who took the naturally-occurring omega-3 fatty acid EPA (a fish oil supplement) before liver surgery. The EMT2 study is a larger study which will recruit 448 men and women with liver metastases from bowel cancer. Trial participants will receive either Icosapent Ethyl (pure EPA derived from fish oil) or placebo (dummy capsules). EMT2 will investigate whether patients who take this supplement before liver surgery and for up to four years after surgery, remain free of recurrence for longer than those who take placebo (dummy capsules)

Condition or disease Intervention/treatment Phase
Liver MetastasisColon CancerDrug: Icosapent EthylOther: PlaceboPhase 3

Detailed Description:

Despite significant advances in diagnosis and treatment of colorectal cancer (CRC), it remains the second most common cause of cancer-related death in the UK. The majority of deaths from CRC are related to distant metastasis, predominantly to the liver. Overall 5-year survival following liver resection and adjuvant chemotherapy for colorectal cancer liver metastases (CRCLM) is, at best, 40-60%. Despite surgery with curative intent, up to 60% of patients develop recurrence within 2 years of surgery. The preliminary EMT study was a Phase II RCT of EPA 2 g daily in patients (n=88) undergoing liver resection surgery for CRCLM. Although there was no difference in the primary endpoint (tumour proliferation index), metastases from the EPA arm had a lower vascularity score (suggesting possible anti-angiogenic activity) than placebo-treated tumours. Although EPA (or placebo) treatment was limited to the pre-operative period, overall survival (OS) and disease-free survival (DFS) were specified as exploratory end-points on the basis that oral dosing with EPA before liver surgery would provide tissue EPA exposure in the immediate peri-operative period with prolonged bioavailability in the post-operative period due to the slow tissue 'washout' kinetics of EPA. Survival analysis demonstrated that the median DFS in the EPA group was 22.6 months compared with 14.7 months in the placebo group. Any DFS benefit was explained by a reduction in CRC recurrence from 12 months after surgery onwards.

The EMT2 study is a randomised, double-blind, placebo-controlled, multi-centre, phase III trial of the omega-3 fatty acid (O3FA) eicosapentaenoic acid (EPA) as the ethyl ester (icosapent ethyl [IPE; Vascepa®]) in patients undergoing liver resection surgery for colorectal cancer liver metastasis (CRCLM) with curative intent designed to determine whether EPA treatment improves Progression-Free Survival (PFS). A key secondary objective is overall survival (OS).

Investigators will recruit adult individuals listed for CRCLM resection with curative intent.

Randomisation will be 1:1 to receive either IPE capsules or placebo capsules. 4 capsules per day containing IPE (equivalent to 4 g EPA-ethyl ester [EE] daily) or 4 placebo capsules per day. Participants will start treatment a prior to CRCLM surgery and will continue to receive treatment for a minimum of 2 years and a maximum of 4 years post-liver resection. Participants are followed up for 60 days beyond the end of treatment.

Participants are clinically assessed 6 months post-operatively (from liver resection) and at 6-monthly intervals thereafter for disease progression/recurrence.

Study Design
Go to
Study Type :Interventional (Clinical Trial)
Estimated Enrollment :448 participants
Allocation:Randomized
Intervention Model:Parallel Assignment
Masking:Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:Prevention
Official Title:A Randomised Placebo-controlled Phase III Trial of the Effect of the Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) on Colorectal Cancer Recurrence and Survival After Surgery for Resectable Liver Metastases
Actual Study Start Date :March 16, 2018
Estimated Primary Completion Date :January 2022
Estimated Study Completion Date :January 2023
Resource links provided by the National Library of MedicineDrug Information available for: Icosapent Ethyl icosapentate Icosapent ethyl
Arms and Interventions
Go to
Arm Intervention/treatment
Experimental: Icosapent Ethyl (EPA-EE)
Soft gelatin capsules containing 1g pure EPA-EE equivalent to 914mg EPA-FFA. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
Drug: Icosapent Ethyl
Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
Other Name: Vascepa

Placebo Comparator: Placebo
Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
Other: Placebo

Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:

Dose: 4 capsules per day




Outcome Measures
Go to

Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Minimum of 2 years follow-up ]
    PFS is defined as the time from randomisation to death (from any cause), first documented evidence of disease progression, new recurrence or clinical deterioration unequivocally due to disease progression


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Minimum of 2 years follow-up ]
    The time from randomisation to death, from any cause (key secondary endpoint)

  2. Safety and Tolerability of Icosapent Ethyl [ Time Frame: Minimum of 2 years follow-up ]
    The number of participants with treatment-emergent adverse events as defined by CTCAE v4.0

  3. Patient reported quality of life 1 [ Time Frame: Minimum of 2 years follow-up ]
    Measured using the EQ-5D questionnaire

  4. Patient reported quality of life 2 [ Time Frame: Minimum of 2 years follow-up ]
    Measured using the EORTC QLQ-C30 questionnaire

  5. Patient reported quality of life 3 [ Time Frame: Minimum of 2 years follow-up ]
    Measured using the QLQ-LMC21 questionnaire

  6. New Primary Cancers [ Time Frame: Minimum of 2 years follow-up ]
    Excluding DCIS, cervical carcinoma in situ, superficial bladder carcinoma where treatment consisted of resection only and non-melanoma skin cancer where treatment consisted of resection or radiotherapy only)


Other Outcome Measures:
  1. Red Blood Cell Membrane EPA content (exploratory endpoint) [ Time Frame: Samples taken at baseline, surgery and 6 months after surgery ]
    EPA content measured at baseline, surgery and 6 months after surgery. Samples taken at selected sites only

  2. Change in lean body mass (exploratory endpoint) [ Time Frame: 6 months and up to 4 years follow up ]
    Change in lean body mass measured by CT scanning during follow-up as assessed by the L3 skeletal muscle index score. Scans reviewed from selected sites only

Eligibility Criteria
Go to

Information from the National Library of MedicineChoosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

  • Aged ≥ 18 years
  • Able to provide written informed consent
  • Histological diagnosis of colorectal cancer with evidence of liver metastases
  • Planned liver resection surgery for colorectal cancer liver metastases with curative intent, including repeat 're-do' colorectal cancer liver metastases surgery (a second independent resection for a separate colorectal cancer liver recurrence)
  • Intention to receive IMP prior to colorectal cancer liver metastases surgery

Exclusion Criteria:

  • Previous CRCLM surgery for the management of the current metastatic disease
  • Incurable extra-hepatic metastases
  • Current (in the last 2 months) or planned regular (>3 doses per week) use of O3FA containing supplements, including fish oil and cod-liver oil supplements
  • Fish/seafood allergy
  • Inability to comply with trial treatment and follow-up schedule
  • Known bleeding tendency/condition (e.g. von Willebrand disease)
  • A previous malignancy within the last 5 years other than:

    • colorectal cancer
    • non-melanoma skin cancer where treatment consisted of resection only or radiotherapy
    • ductal carcinoma in situ (DCIS) where treatment consisted of resection only
    • cervical carcinoma in situ where treatment consisted of resection only
    • superficial bladder carcinoma where treatment consisted of resection only
  • A previous malignancy where the patient has been disease free for ≤ 5 years
  • Pregnant or breastfeeding women or women of childbearing potential not willing to use effective contraceptive measures. Women of childbearing potential are defined as fertile, following menarche and until becoming post-menopausal, unless permanently sterile
  • Men defined as fertile (post-pubescent and not permanently sterile by vasectomy or bilateral orchidectomy) and not willing to use effective contraceptive measures if appropriate.
Contacts and Locations
Go to

Information from the National Library of MedicineTo learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03428477


Contacts
Contact: Mark Hull0113 343 8650m.a.hull@leeds.ac.uk

Locations
United Kingdom
Hampshire Hospitals NHS Foundation TrustRecruiting
Basingstoke, Royal Hampshire, United Kingdom, RG24 9NA
Contact: Fenella Welsh
Aintree University Hospitals NHS Foundation TrustRecruiting
Aintree, United Kingdom
Contact: Stephen Fenwick
University Hospitals Birmingham NHS Foundation TrustRecruiting
Birmingham, United Kingdom
Contact: Keith Roberts
Cambridge UniversityHospitals NHS Foundation TrustNot yet recruiting
Cambridge, United Kingdom
Contact: Elizabeth Smyth
Leeds Teaching Hospitals NHS Foundation TrustRecruiting
Leeds, United Kingdom
Contact: Giles Toogood
Royal Free London NHS Foundation TrustNot yet recruiting
London, United Kingdom
Contact: Brian Davidson
Newcastle Upon Tyne Hospitals NHS Foundation TrustNot yet recruiting
Newcastle, United Kingdom
Contact: John Hammond
Nottingham University Hospitals NHS TrustRecruiting
Nottingham, United Kingdom
Contact: Dhanny Gomez
Sheffield Teaching Hospitals NHS Foundation TrustRecruiting
Sheffield, United Kingdom
Contact: Mark Peterson
University Hospital Southampton NHS Foundation TrustRecruiting
Southampton, United Kingdom
Contact: Zaed Hamady
Sponsors and Collaborators
Mark A Hull, PhD FRCP
Yorkshire Cancer Research
Amarin Pharma Inc.
Investigators
Principal Investigator:Mark HullUniversity of Leeds
Study Documents (Full-Text)

Documents provided by Mark A Hull, PhD FRCP, University of Leeds:
Study Protocol [PDF] February 26, 2019
More Information
Go to
Responsible Party:Mark A Hull, PhD FRCP, Prof Mark Hull, University of Leeds
ClinicalTrials.gov Identifier:NCT03428477 History of Changes
Other Study ID Numbers:MO16/053
First Posted:February 9, 2018 Key Record Dates
Last Update Posted:November 1, 2019
Last Verified:October 2019
 
 
3. 

Same-Day Antiretroviral Therapy Initiation


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04032028
Recruitment Status : Recruiting
First Posted : July 25, 2019
Last Update Posted : August 22, 2019
Sponsor:
Information provided by (Responsible Party):
Thai Red Cross AIDS Research Centre

Study Description
Go to
Brief Summary:
Data from a total of 2,500 walk-in or referred individuals who have been confirmed (diagnosed) HIV positive and accessing care and treatment services at the hospitals targeted by this study will be examined. The starting period for this project is estimated to be the last quarter (Q4) of fiscal year 2018.

Condition or disease
HIV Infections

Detailed Description:
This 24-month observation study will be conducted in 13 hospitals of 5 provinces in Thailand: Chiang Rai, Chiang Mai, Ubon Ratchathani, Chonburi, and Songkhla. The research team of TRCARC will collect and analyze secondary and de-identified data from the hospitals' databases. In each site, clients who agree to receive Same-Day ART service will go through standard of care procedures at each hospital, which include: post-test counseling and psychosocial support, baseline lab test, clinical screening, and physical examination. The drug regimen prescribed for clients will mirror the first line ART regimen in Thailand's national guideline, which is tenofovir (TDF), emtricitabine (FTC), and efavirenz (EFV). Retention of the clients will reflect that of the hospital's protocol, and CD4 and viral load will be tested according to the national guideline.
Study Design
Go to
Study Type :Observational
Estimated Enrollment :2500 participants
Observational Model:Cohort
Time Perspective:Prospective
Official Title:The Thai Red Cross AIDS Research Centre
Actual Study Start Date :April 1, 2018
Estimated Primary Completion Date :December 1, 2020
Estimated Study Completion Date :December 1, 2025
Resource links provided by the National Library of MedicineMedlinePlus related topics: HIV/AIDS
Groups and Cohorts
Go to


Outcome Measures
Go to

Primary Outcome Measures :
  1. Acceptance [ Time Frame: 5 years ]
    Acceptance of Same-Day ART

  2. Type of Clients [ Time Frame: 5 years ]
    Type of Clients (newly diagnosed or re-engaged)

  3. Number of clients categorized by demographic characteristics [ Time Frame: 5 years ]
    Demographic Characteristics: age (years), gender (sex at birth and gender identity), risk behavior(s), and reason(s) for HIV testing

  4. Number of clients with each clinical characteristic [ Time Frame: 5 years ]
    Clinical Characteristics based on Thailand's national guidelines (anti-HIV, creatinine, alanine transaminase, syphilis serology, hepatitis B antigen, hepatitis C antibodies, urinalysis, chest X-ray, CD4 count, CDC stage, comorbidity)

  5. Number of clients with each ART drug regimen differ from first line ART regimen [ Time Frame: 5 years ]
    Drug regimen, if different from first line drug (TDF, FTC, EFV)

  6. Duration between date of HIV diagnosis and date of ART initiation [ Time Frame: 5 years ]
    Duration between date of HIV diagnosis and date of ART initiation

  7. Number of clients with each clinical exclusion criteria [ Time Frame: 5 years ]
    Clinical exclusion criterias : suspected TB, suspected cryptococcal meningitis, suspected serious OIs

  8. Duration between date of ART initiation to date of being successfully transferred and date of ART continuation [ Time Frame: 5 years ]
    Duration of linkage to care, if applicable (date of being successfully transferred and date of ART continuation)

  9. Retention [ Time Frame: 5 years ]
    Retention (retention in care, discontinued ART, loss to follow-up, death) at month 1, month 3, month 6, and month 12 after ART initiation

  10. Viral load count [ Time Frame: 5 years ]
    Viral load count (VL tested, percentage of VL suppressed, and dates of VL suppressed)

Eligibility Criteria
Go to

Information from the National Library of MedicineChoosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study: Child, Adult, Older Adult
Sexes Eligible for Study: All
Sampling Method: Probability Sample
Study Population
All persons who have tested HIV positive will be examined.
Criteria

Inclusion Criteria:

  1. Thai nationals
  2. HIV-positive status
  3. Acceptance of Same-Day ART

Exclusion Criteria:

1. not Acceptance of Same-Day ART

Contacts and Locations
Go to

Information from the National Library of MedicineTo learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04032028


Contacts
Contact: Nittaya Phanuphak, MD, PhD881 8253544nittaya.p@prevention-trcarc.org
Contact: Reshmie Ramautarsing, MD,+662 2530996reshmie@prevention-trcarc.org

Locations
Thailand
Thai Red Cross AIDS Research CentreRecruiting
Pathum Wan, Bangkok, Thailand, 10330
Hangdon HospitalRecruiting
Hang dong, Chiang Mai, Thailand, 50300
Contact: Hataichanok Chawengchutirat, M.D.
Contact: Jantana Meechure (+66)91-157-1199 jantana652@gmail.com
Nakornping HospitalRecruiting
Mae Rim, Chiang Mai, Thailand, 50180
Contact: Prattana Leenasirimakul, M.D. (+66)89-700-2922 leeprattana@gmail.com
Contact: Siripim Kamphaengkham (+66)89-850-1488 siripim24@gmail.com
Sarapee HospitalRecruiting
Saraphi, Chiang Mai, Thailand, 50140
Contact: Amarin Norchaiwong (+66)89-998-7860 amarin.105@hotmail.com
Wat Yannasangwararam HospitalRecruiting
Bang Lamung, Chonburi, Thailand, 00084
Contact: Nuttarea Nitisuk (+66)81-060-3847 pootjubpear@gmail.com
Queen Savang Vadhana Memorial HospitalRecruiting
Siracha, Chonburi, Thailand, 20110
Contact: Teerarat Shanthachol, M.D. (+66)89-767-1877 nuiteerarat@gmail.com
Contact: Pornpen Methajittiphan (+66)81-576-2474 purematha@yahoo.com
Hat Yai HospitalRecruiting
Hat Yai, Song Khla, Thailand, 90110
Contact: Preudtipong Noopetch, M.D. Jasommhai@hotmail.com
Contact: Waranee Teerakun (+66)91-463-6693 waranee.pp@hotmail.com
Sunpasitthiprasong HospitalRecruiting
Udon Thani, Ubon Ratchathani, Thailand, 34000
Contact: Suriyong Boonprachern (+66)84-550-0379 suriyong.b@hotmail.com
Sanpatong HospitalRecruiting
Chiang Mai, Thailand, 50120
Contact: Rungprakai Injong, M.D. (+66)80-505-6151 Rungprakai_kwan@hotmail.com
Contact: Yaowalak Siriwarothai (+66)81-022-6231 yaowaluk.s3p@gmail.com
Chiang Mai HospitalRecruiting
Chiang Mai, Thailand, 50300
Contact: Jujira Srinukul (+66)97-987-5497 junjira.w@gmail.com
Chiang rai prachanukor HospitalRecruiting
Chiang Rai, Thailand, 57000
Contact: Suwimon Khusuwan, M.D. (+66)53-711-300 ngornaja@yahoo.com
Contact: Supawadee Pongprapass (+66)81-961-6900 npudit@hotmail.com
Sponsors and Collaborators
Thai Red Cross AIDS Research Centre
More Information
Go to
Responsible Party:Thai Red Cross AIDS Research Centre
ClinicalTrials.gov Identifier:NCT04032028 History of Changes
Other Study ID Numbers:Same-Day ART Initiation
First Posted:July 25, 2019 Key Record Dates
Last Update Posted:August 22, 2019
Last Verified:August 2019
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 217
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
7337 Re: Three Vascepa trial protocols currently recruiting per clinicaltrials.gov Public_Heel 0 6/30/2020 10:46:29 AM
7339 Re: Three Vascepa trial protocols currently recruiting per clinicaltrials.gov ex_hacker202 0 6/30/2020 11:56:11 AM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...